A further study then demonstrated that when NLRP3 or caspase-1 was knocked out in transgenic AD model mice, IL-1β activation was substantially reduced, providing support for the role of this activation pathway in vivo (Heneka et al., 2013). This evidence concerns the gene CASP1 and Alzheimer disease.